Video Reports

Embed this video

Copy Code

Link to this video

Get LinkEmbedLicenseRecommend (-)Print
Bookmark and Share

By Bill Buhr | 08-07-2009 10:00 AM

Our Take on IPO Cumberland's Growth Prospects

Health-care analyst Brian Laegeler likes the fact that specialty pharma IPO Cumberland is already profitable, but a weak pipeline and a pricey offer price are concerns.

Bill Buhr: Hi, I'm Bill Buhr, IPO strategist with Morningstar. While July was a pretty slow month in the IPO space, August looks like it's picking up, as two companies will come to market in the next week. One of those, Cumberland Pharmaceuticals, is looking to raise $100 million.

Joining me today is specialty pharma analyst Brian Laegeler to talk about Cumberland. Brian, thanks for coming.

Brian Laegeler: Thanks for having me.

Buhr: Now, where does Cumberland fit into specialty pharma?

Laegeler: Well, Cumberland is a specialty marketer, like King Pharma or Forest Labs. These types of companies have limited discovery efforts, and what they do is acquire most of their products. So the power of this business model is in concentrating several products down one audience so they can maximize their sales revenue per salesperson.

For Cumberland, their specialty is hospitals. They've got 30 right now, specializing in the hospital-sales-force side. They're going to expand to 77, post-IPO.

Read Full Transcript
{0}-{1} of {2} Comments
{0}-{1} of {2} Comment
  • This post has been reported.
  • Comment removed for violation of Terms of Use ({0})
    Please create a username to comment on this article